Company intelligence / Profile preview

Ractigen Therapeutics

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Ractigen’s lead program, RAG-01 for NMIBC, received FDA Fast Track Designation in May 2024. The company has dosed patients in Phase I clinical trials for both RAG-01 and the ALS program RAG-17. Early data from investigator-led studies of RAG-17 show promising safety and efficacy signals. Preclinical work supports the potential of their saRNA/siRNA approaches to address previously undruggable or monogenic diseases by upregulating or silencing specific genes as needed

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: small activating RNA (saRNA)small interfering RNA (siRNA)oligonucleotides
Industry: Biotech

Drug pipeline

14 assets

RAG-01

13 more assets in the full pipeline.

Request access →

Partnerships

University Medical Center Utrecht for neurodevelopmental disorder research using saRNAs

Beyond the preview

Go deeper on Ractigen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ractigen Therapeutics.

Explore the full profile